Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Mar 23;59(6):1469–1477. doi: 10.2337/db09-0502

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 5. — EP1013 therapy prevents both IgM and IgG alloantibody formation, both as a single agent and in combination with CTLA4-Ig. Sera were collected via tail vein bleeds prospectively and stored for bulk analysis at the completion of the study using a donor-specific cellular ELISA to measure alloantibody production. A: IgM alloantibody formation was detected in vehicle-treated control animals (●), while treatment with EP1013 (○), CTLA4-Ig (▲), or EP1013+CTLA4-Ig (△) resulted in a significant reduction in IgM alloantibody formation (P < 0.02 for all treatment groups vs. control). B: Similar results were obtained when IgG alloantibody levels were assessed, with vehicle-treated control animals becoming highly sensitized within 2 weeks post-transplantation (●). IgG allosensitization was prevented after treatment with EP1013 (○), CTLA4-Ig (▲), or EP1013+CTLA4-Ig (△) (P < 0.05 for each treatment group vs. control). A minimum of n = 5 serum samples from each treatment group were analyzed in duplicate for these assays. OD, optical density.